Table 3.

Estimated incidence of TdP among users* of specific TdP-classified antiarrhythmic, antihypertensive, anti-infective, urology, gastrointestinal, cancer or antirheumatic drugs in patients aged ≥65 and 18–64 years during 2006–2017 (the number of TdP cases using the specific drug are shown in parentheses)

Therapeutic group and specific drug	TdP class	TdP per 100 000 ≥65 years (number of TdP cases)	Number of users ≥65 years	TdP per 100 000 18–64 years (number of TdP cases)	Number of users 18–64 years
Antiarrhythmic drugs
Disopyramide	1	231.2 (9)	3 893	0	1 993
Sotalol	1	81.1 (31)	38 203	41.2 (6)	14 547
Amiodarone	1	61.3 (13)	21 201	66.5 (6)	9 029
Flecainide	1	23.3 (2)	8 566	10.2 (1)	9 842
Dronedarone	1	9.5 (1)	10 552	33.2 (2)	5 944
Antihypertensive drugs
Isradipine	3	33.1 (3)	9061	0	3846
Antinfective drugs
Erythromycin	1	0	71 884	0.3 (1)	320 592
Ciprofloxacin	1	0.5 (3)	589 531	0.1 (1)	703 926
Moxifloxacin	1	15.1 (2)	13 190	0	21 572
Flukonazole	1	1.2 (2)	165 084	0	471 278
Posaconazole	3	132 (1)	756	0	1 505
Metronidazole	3	0	204 846	0.2 (1)	592 134
Drugs in urology
Alfuzosin	2	4.6 (11)	239 618	1.5 (2)	136 139
Solifenacin	3	2.5 (2)	80 771	2.3 (1)	42 623
Tolterodine	3	3.4 (4)	118 155	1.9 (1)	52 520
Gastrointestinal drugs
Papaverine	1	1.8 (1)	54 797	0.9 (1)	115 111
Metoclopramide	3	1.7 (4)	237 601	0.7 (2)	273 331
Loperamide	3	1.6 (3)	189 086	1.2 (2)	160 901
Drugs in cancer
Tamoxifen	2	2.9 (1)	34 252	0	32 127
Tacrolimus	2	0	2 845	24.8 (2)	2 845
Antireumatic drug
Hydoxychloroquine	3	21.6 (2)	9 247	5.0 (1)	19 929

*A person is considered to have used a drug if the person has a dispensed prescription lasting until or beyond the TdP event day. See the Methods section for details.

TdP, torsades de pointes.